Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. (Q51297212)

2 April 2018

title

Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. (English)

1 reference

2 April 2018

1 reference

Nelson Leung-Sang Tang

1

1 reference

2 April 2018

Jean Woo

9

1 reference

2 April 2018

Winnie Yeo

object named as

Winnie Yeo

10

0 references

author name string

Chen Di Liao

2

1 reference

2 April 2018

Xingyan Wang

3

1 reference

2 April 2018

Frankie K F Mo

4

1 reference

2 April 2018

Vicky T C Chan

5

1 reference

2 April 2018

Rita Ng

6

1 reference

2 April 2018

Elizabeth Pang

7

1 reference

2 April 2018

Joyce J S Suen

8

1 reference

2 April 2018

publication date

10 November 2012

1 reference

2 April 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

2 April 2018

volume

139

1 reference

2 April 2018

issue

3

1 reference

2 April 2018

page(s)

419-427

1 reference

2 April 2018

https://scigraph.springernature.com/pub.10.1007/s00432-012-1345-5

exact match

0 references

cites work

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Haploview: analysis and visualization of LD and haplotype maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Neutropenia in 6 ethnic groups from the Caribbean and the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Nuclear receptor PXR, transcriptional circuits and metabolic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Association of SRD5A2 variants and serum androstane-3alpha,17beta-diol glucuronide concentration in Chinese elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

CYP3A5 phenotype-genotype correlations in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Population-based differences in treatment outcome following anticancer drug therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

Analysis of CYP3A4 genetic polymorphisms in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1345-5

High-throughput SNP genotyping by single-tube PCR with Tm-shift primers

21 January 2018

1 reference

12 December 2020

Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients

1 reference

12 December 2020

Ethnic differences in drug metabolism and toxicity from chemotherapy

1 reference

12 December 2020

CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.

1 reference

12 December 2020

Association of genetic variations in aromatase gene with serum estrogen and estrogen/testosterone ratio in Chinese elderly men.

1 reference

12 December 2020

Inter-ethnic differences--how important is it in cancer treatment?

1 reference

12 December 2020

Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients

1 reference

12 December 2020

10.1007/S00432-012-1345-5

Identifiers

DOI

1 reference

2 April 2018

1 reference

2 April 2018